新型直接凝血酶抑制剂、实验室监测及逆转剂的实用综述
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents.
作者信息
Joppa Stephanie A, Salciccioli Justin, Adamski Jill, Patel Salma, Wysokinski Waldemar, McBane Robert, Al-Saffar Farah, Esser Heidi, Shamoun Fadi
机构信息
Department of Cardiology, Mayo Clinic, Phoenix, AZ 85054, USA.
Whipps Cross University Hospital, London E11 1NR, UK.
出版信息
J Clin Med. 2018 Feb 11;7(2):29. doi: 10.3390/jcm7020029.
Abstract
Millions of patients in the United States use anticoagulation for a variety of indications, such as the prevention of stroke in those with atrial fibrillation (AF) and the treatment and prevention of venous thrombosis. For over six decades warfarin was the only available oral anticoagulant, but now several DOACs are available and their use has become more prevalent in recent years. In spite of this increased use, many physicians remain reluctant to prescribe DOACs due to concerns about bleeding and reversibility.
摘要
在美国，数百万患者因各种适应症而使用抗凝药物，例如预防心房颤动（AF）患者的中风以及治疗和预防静脉血栓形成。六十多年来，华法林一直是唯一可用的口服抗凝剂，但现在有几种直接口服抗凝剂（DOACs）可供使用，并且近年来它们的使用变得更加普遍。尽管使用量有所增加，但由于担心出血和可逆性，许多医生仍然不愿意开DOACs。
相似文献
1
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents.新型直接凝血酶抑制剂、实验室监测及逆转剂的实用综述
J Clin Med. 2018 Feb 11;7(2):29. doi: 10.3390/jcm7020029.
2
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.直接口服抗凝剂与华法林在非瓣膜性心房颤动中的围手术期结局。
Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457.
3
Oral Anticoagulants Beyond Warfarin.口服抗凝药物：华法林以外的选择
Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:551-575. doi: 10.1146/annurev-pharmtox-032823-122811. Epub 2023 Sep 27.
4
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.直接口服抗凝药与华法林在心房颤动患者中的比较：按年龄和性别进行交互测试的随机临床试验的患者水平网络荟萃分析。
Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5.
5
Self-reported adherence to direct oral anticoagulants versus warfarin therapy in a specialized thrombosis service-a cross-sectional study of patients in a Canadian Health Region.在一家专门的血栓形成治疗机构中，自我报告的直接口服抗凝剂与华法林治疗的依从性——对加拿大一个健康区域患者的横断面研究
Eur J Clin Pharmacol. 2023 Jan;79(1):117-125. doi: 10.1007/s00228-022-03418-8. Epub 2022 Nov 18.
6
Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.直接口服抗凝剂和华法林治疗心房颤动患者的处方模式和结局：真实世界分析。
J Cardiovasc Pharmacol Ther. 2019 Sep;24(5):428-434. doi: 10.1177/1074248419841634. Epub 2019 Apr 29.
7
Contemporary Perioperative Management of Direct Oral Anticoagulants.直接口服抗凝剂的当代围手术期管理。
Adv Anesth. 2022 Dec;40(1):93-109. doi: 10.1016/j.aan.2022.06.002.
8
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.口服抗凝剂用于静脉血栓栓塞性疾病的一级预防、治疗和二级预防，以及用于心房颤动的卒中预防：系统评价、网状荟萃分析和成本效益分析。
Health Technol Assess. 2017 Mar;21(9):1-386. doi: 10.3310/hta21090.
9
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.维生素K拮抗剂：与直接口服抗凝剂相比，在心房颤动患者预防中风方面的相对优缺点
J Thromb Thrombolysis. 2017 Apr;43(3):365-379. doi: 10.1007/s11239-016-1446-0.
10
Challenges of Anticoagulant Therapy in Atrial Fibrillation-Focus on Gastrointestinal Bleeding.房颤抗凝治疗面临的挑战-关注胃肠道出血。
Int J Mol Sci. 2023 Apr 7;24(8):6879. doi: 10.3390/ijms24086879.
引用本文的文献
1
The effect of anticoagulation therapy on the surgical outcomes of minimally invasive major gastrointestinal surgery.抗凝治疗对微创大型胃肠手术手术结局的影响。
Surg Endosc. 2025 Feb;39(2):1016-1024. doi: 10.1007/s00464-024-11465-8. Epub 2024 Dec 16.
2
Efficacy and safety of direct oral anticoagulants versus warfarin in the treatment of cerebral venous sinus thrombosis.直接口服抗凝剂与华法林治疗脑静脉窦血栓形成的疗效和安全性
Acta Neurol Belg. 2024 Oct;124(5):1655-1662. doi: 10.1007/s13760-024-02586-x. Epub 2024 Jul 10.
3
A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model.一种具有体内快速作用和特异性单分子逆转剂的功能性 RNA 折纸作为直接凝血酶抑制剂。
Mol Ther. 2024 Jul 3;32(7):2286-2298. doi: 10.1016/j.ymthe.2024.05.002. Epub 2024 May 7.
4
Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding.达比加群：药物及其剂量与中风和出血风险的临床关联。
Perspect Clin Res. 2023 Jan-Mar;14(1):26-31. doi: 10.4103/picr.picr_171_21. Epub 2022 Nov 29.
5
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice.直接口服抗凝剂：从随机临床试验到真实世界临床实践
Front Pharmacol. 2021 May 26;12:684638. doi: 10.3389/fphar.2021.684638. eCollection 2021.
6
Portal vein thrombosis: A concise review (Review).门静脉血栓形成：简要综述（综述）
Exp Ther Med. 2021 Jul;22(1):759. doi: 10.3892/etm.2021.10191. Epub 2021 May 13.
7
Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery.直接口服抗凝剂（DOACs）与股骨颈骨折：规范围手术期管理及手术时机
J Clin Orthop Trauma. 2021 Jan;12(1):138-147. doi: 10.1016/j.jcot.2020.08.005. Epub 2020 Aug 23.
8
Retrospective Review on the Safety and Efficacy of Direct Oral Anticoagulants Compared With Warfarin in Patients With Cirrhosis.肝硬化患者中直接口服抗凝剂与华法林安全性和有效性的回顾性研究
Fed Pract. 2020 Oct;37(10):479-485. doi: 10.12788/fp.0058.
9
Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation.慢性肾脏病及其对心房颤动患者血栓前状态的影响。
J Clin Med. 2020 Aug 1;9(8):2476. doi: 10.3390/jcm9082476.
10
Therapeutic strategies for thrombosis: new targets and approaches.血栓治疗策略：新靶点和新方法。
Nat Rev Drug Discov. 2020 May;19(5):333-352. doi: 10.1038/s41573-020-0061-0. Epub 2020 Mar 4.
本文引用的文献
1
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林治疗稳定的外周动脉或颈动脉疾病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
2
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.利伐沙班或阿哌沙班相关大出血的凝血酶原复合物浓缩物管理：一项队列研究。
Blood. 2017 Oct 12;130(15):1706-1712. doi: 10.1182/blood-2017-05-782060. Epub 2017 Aug 23.
3
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.达比加群酯逆转剂依达鲁珠单抗：全队列分析。
N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11.
4
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.安达西尼α用于治疗与Xa因子抑制剂相关的急性大出血。
N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30.
5
Ciraparantag for enoxaparin reversal: Adding to the evidence.西帕曲班用于依诺肝素逆转：补充证据
Thromb Res. 2016 Oct;146:106-107. doi: 10.1016/j.thromres.2016.08.013. Epub 2016 Aug 13.
6
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.西帕帕拉坦可安全、完全地逆转低分子量肝素的抗凝作用。
Thromb Res. 2016 Oct;146:113-118. doi: 10.1016/j.thromres.2016.07.008. Epub 2016 Jul 18.
7
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.急性病医学患者贝曲西班的延长血栓预防。
N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.
8
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.依达赛珠单抗用于逆转 Xa 因子抑制剂的活性。
N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11.
9
Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.健康受试者口服或经鼻胃管给予阿哌沙班溶液或碾碎片剂制剂的相对生物利用度
Clin Ther. 2015 Aug;37(8):1703-12. doi: 10.1016/j.clinthera.2015.05.497. Epub 2015 Jul 15.
10
National Trends in Ambulatory Oral Anticoagulant Use.门诊口服抗凝剂使用的全国趋势。
Am J Med. 2015 Dec;128(12):1300-5.e2. doi: 10.1016/j.amjmed.2015.05.044. Epub 2015 Jul 2.
Zotero 插件